SVB Leerink reiterated coverage on Compugen with a new price target

4/6/21 7:41:35 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

SVB Leerink reiterated coverage of Compugen with a rating of Outperform and set a new price target of $16.00 from $19.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CGEN

Date	Price Target	Rating	Analyst
1/13/2025	$4.00	Outperform	Oppenheimer
8/5/2022	$2.00	Buy → Hold	Jefferies
2/25/2022	$17.00 → $14.00	Outperform	Oppenheimer
2/25/2022	$16.00 → $9.00	Outperform	SVB Leerink